Author:
Kalhan A.,Gharibi B.,Vazquez M.,Jasani B.,Neal J.,Kidd M.,Modlin I. M.,Pfragner R.,Rees D. A.,Ham J.
Publisher
Springer Science and Business Media LLC
Subject
Cell Biology,Cellular and Molecular Neuroscience,Molecular Biology
Reference45 articles.
1. Rubin J, Ajani J, Schirmer W, Venook AP, Bukowski R, Pommier R et al (1999) Octreotide acetate long-acting formulation versus open-label subcutaneous octreotide acetate in malignant carcinoid syndrome. J Clin Oncol 17:600–606
2. Arnold R, for the PROMID Study Group (2009) Placebo-controlled, double-blind, prospective, randomized study of the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID study group. J Clin Orthod 27(28):4656–4663. doi: 10.1200/JCO.2009.22.8510 , ASCO GI Cancers Symposium
3. Adams RL, Adams IP, Lindow SW, Zhong W, Atkin SL (2005) Somatostatin receptors 2 and 5 are preferentially expressed in proliferating endothelium. Brit J Cancer 92:1493–1498
4. Saras J, Gronberg M, Stridsberg M, Oberg KE, Janson ET (2007) Somatostatin induces rapid contraction of neuroendocrine cells. FEBS Lett 581:1957–1962
5. Oberg K (1994) Biology, diagnosis and treatment of neuroendocrine tumors of the gastrointestinal tract. Curr Opin Oncol 6:441–451
Cited by
23 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献